Pricing Log in Create free account
Friday 6 November 2026 Export HIMS’s income statement to Excel — free account

Hims & Hers Health, Inc.

HIMS Healthcare Drug Manufacturers Specialty & Generic

Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.

Revenue
+38.3%
EPS
−294.7%
Free cash flow
+5.09%
Total debt
+40.8%

Quarter to June 2026, against a year earlier

24.11 2.55 −9.56%
Market cap
$5.6B
P/E
0.0×
Fwd P/E
−49.4×
Dividend yield
—
F-score
4/9
Altman Z
4.10
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Hims & Hers Health, Inc. (HIMS) EV/EBITDA

Alert me on EV/EBITDA

Hims & Hers Health, Inc. has no meaningful EV/EBITDA: its trailing twelve-month EBITDA is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 262× (July 2024) — the current reading is the lowest in ten years.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 47.3× (28.23%)
FY2024 66.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2020 0.0× —
FY2019 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 0.0× —
Mar 2026 119× 150.99%
Dec 2025 47.3× (43.22%)
Sep 2025 83.4× 16.45%
22 more quarters

Against its own ten years

Low 0.0× High 262×
Ten-year median 0.0×
Current reading's percentile 72

EV/EBITDA against peers

Company EV/EBITDA
HIMS Hims & Hers Health, Inc. n/m
AMLX Amylyx Pharmaceuticals, Inc. compare n/m
SUPN Indivior Pharmaceuticals Inc. compare 7.0×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 14.3×
LNTH Lantheus Holdings, Inc. compare 16.7×
LQDA Liquidia Corporation compare 22.7×
RDY Dr. Reddy's Laboratories Ltd compare 22.9×
ALKS Alkermes plc compare 37.9×
KNSA Kiniksa Pharmaceuticals International, plc compare 48.0×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on HIMS